Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management

WOODCLIFF LAKE, N.J., Aug. 15, 2013 /PRNewswire/ -- Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity management. The website, "Closing the Gap: Obesity Management for Employers," can be accessed at http://ctgobesity.com/.

"We know from our research that most employers consider obesity to be a top employee health challenge," said Dave Martin, Vice President of Managed Markets, Value and Access for Eisai.  "While there are some helpful resources available for employers, we also noted significant gaps; therefore, we decided to build this all-inclusive website as a companion to an e-newsletter, in partnership with The Benfield Group."

Both the e-newsletter and the website will provide employers access to articles, links to other sites and other downloadable tools including:  

Closing the Gap in Obesity Management Solutions: The Importance of Integrating New Prescription Medications into Employer Strategies to Help Reduce Obesity in their Employee and Dependent Populations. A publication that reviews the challenges and opportunities of obesity management and provides recommendations from an Eisai-sponsored advisory board of leading employer health benefit decision-makers on approaches to update employer strategies.

Blueprint for Health™: A free, interactive online tool available through the American College of Occupational and Environmental Medicine (ACOEM) that allows employers to estimate direct and indirect costs associated with the conditions they select, by entering key employee demographics.

Your Weight Matters(SM) Campaign (YWM): The Your Weight Matters Campaign was developed by the Obesity Action Coalition (OAC) and sponsored by Eisai. The Your Weight Matters Campaign encourages all Americans to measure their weight and take the Campaign Challenge by making a pledge to talk to a healthcare provider about their weight and its impact on their health. All Campaign participants receive a FREE toolkit to help them prepare for the conversation of weight with their healthcare provider.

The content for the Blueprint for Health and Your Weight Matters Campaign websites are not controlled by Eisai.

Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Media Inquiries 

Investor Inquiries

Marcia Diljak

Alex Scott

Eisai Inc.

Eisai Inc.

(201) 746-2236 

(201) 746-2177

SOURCE Eisai Inc.

Type Press Release

Date Released August 15, 2013

RECENT RELEASES
Mar 5, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC...

Feb 28, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta...

Jan 18, 2024

Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields